Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis

Official Title

Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)

Brief Summary

      The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared
      to conventional treatment in patients with a relapse of Wegener Granulomatosis with or
      without ongoing steroids, and/or immunosuppressive therapy. Further, to evaluate the safety
      and quality of life of gusperimus treatment compared to standard treatment in patients with
      relapse of Wegener Granulomatosis receiving glucocorticoids.

Detailed Description

      Wegener Granulomatosis without treatment is life-threatening. The standard treatment with
      corticosteroids and cyclophosphamide is usually effective at controlling active disease.
      However, disease relapse is frequent and requires increased exposure to these toxic drugs. In
      other patients initiation or continuation of these standard drugs is contraindicated due to
      intolerable side effects. No well-established therapy is available for relapsing patients.
      They may suffer severe organ damage due to progressive disease, or may die. The proposed
      indication for gusperimus is the treatment of relapsing Wegener Granulomatosis. The aim of
      therapy with gusperimus is to induce and maintain remission thereby avoiding further
      cyclophosphamide and reducing corticosteroid exposure.

Study Phase

Phase 3

Study Type


Primary Outcome

Response rate

Secondary Outcome

 Time to response


Wegeners Granulomatosis


Gusperimus + glucocorticoids

Study Arms / Comparison Groups

 Test group - gusperimus
Description:  Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 2011

Completion Date

January 2015

Primary Completion Date

November 2012

Eligibility Criteria

        Inclusion Criteria:

          1. Documented diagnosis of Wegener's Granulomatosis (WG) according to the American
             College of Rheumatology classification criteria.

          2. Diagnosis of WG at least 6 months before entry and initial induction therapy with a
             combination of Glucocorticoids and an immunosuppressive (Cyclophosphamide or
             Methotrexate) or rituximab.

          3. Relapse of WG with or without ongoing Glucocorticoids, and/or immunosuppressive
             therapy with Azathioprine/Mycophenolate Mofetil/Methotrexate or Leflunomide. The
             minimum disease activity is defined by the presence of one new/worse major or three
             new/worse minor BVAS (version 3) items.

          4. Patients between 18 - 75 years.

          5. Medically acceptable and reliable contraception method during the study course. (Women
             should not become pregnant for at least 6 months after Cyclophosphamide treatment).

          6. Written informed consent for study participation given by the patient.

          7. Patients able and prepared to self-administer the study medication or having a
             relative/third person able to do it.

          8. Ability to read, understand and record information required by protocol

        Exclusion Criteria:

          1. Other multi-system autoimmune disorders, including systemic lupus erythematosus and
             anti-Glomerular Basement Membrane disease.

          2. Systemic vasculitis due to a viral infection.

          3. Cyclophosphamide therapy intolerance, hypersensitivity or contraindication to
             Cyclophosphamide (active substance or any of the excipients) in patients with severe
             relapse of WG.

          4. Hypersensitivity or contraindication to

               -  Spanidin (active substance or any of the excipients) or

               -  both Methotrexate (active substance or any of the excipients) and
                  Azathioprine(active substance or any of the excipients) or

               -  methylprednisolone, prednisolone or other corticosteroids (active substance or
                  any of the excipients).

          5. Underlying medical conditions, which in the opinion of the Investigator place the
             patient at an unacceptable risk level for participating in a study.

          6. Previous randomisation in this study.

          7. Cyclophosphamide , intravenous immunoglobulin, anti-cytokine biologic therapies,
             plasma exchange or Abatacept in the three months prior to entry to the trial.
             Rituximab, Alemtuzumab or stem cell transplantation is not permitted in the six months
             prior to entry to the trial.

          8. Previous treatment with gusperimus.

          9. Participation in another clinical trial with investigational drugs within the last 3
             months before screening or during the present trial period.

         10. Pregnant or breast-feeding females.

         11. Active bacterial/viral infection (Human Immunodeficiency Virus, Hepatitis B, Hepatitis
             C, Tuberculosis).

         12. Patients with Glomerular Filtration Rate (eGFR) < 15 mL/min/1.73m2.

         13. Alanine transaminase (ALT), Aspartate aminotransferase (AST), bilirubin, and Alkaline
             phosphatase (ALP) levels above 2 x the upper normal limit.

         14. Inadequate bone-marrow function: White Blood Cells (WBC) < 4000/mm3, haemoglobin < 8
             g/dL, neutrophils < 2500/mm3, platelets < 100 000/mm3.




18 Years - 75 Years

Accepts Healthy Volunteers



David Jayne, MD, , 

Location Countries

Czech Republic

Location Countries

Czech Republic

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Nordic Pharma SAS

Study Sponsor

David Jayne, MD, Principal Investigator, Addenbrookes Hospital, Cambridge, United Kingdom

Verification Date

January 2015